New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2012
10:00 EDTTEVA, MDLZ, RCL, ZIOP, STX, NOV, BXP, XEL, PTEN, IEX, VOLC, SF, NVSOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: IDEX Corp. (IEX) downgraded to Hold from Buy at Brean Capital... National Oilwell (NOV) downgraded to Outperform from Buy at CLSA... Novartis (NVS) downgraded to Hold from Buy at Deutsche Bank... Patterson-UTI Energy (PTEN) downgraded to Outperform from Buy at CLSA... Seagate (STX) downgraded to Underweight from Neutral at JPMorgan... Stifel Financial (SF) downgraded to Underperform from Market Perform at Wells Fargo... Xcel Energy (XEL) downgraded to Neutral from Outperform at Macquarie... Ziopharm (ZIOP) downgraded to Hold from Buy at Jefferies... Boston Properties (BXP) downgraded to Hold from Buy at Stifel Nicolaus... Volcano (VOLC) downgraded to Neutral from Outperform at Credit Suisse... Teva (TEVA) downgraded to Market Perform from Outperform at Leerink... Royal Caribbean (RCL) downgraded to Neutral from Buy at Longbow... Mondelez (MDLZ) downgraded to Hold from Buy at Argus.
News For IEX;NOV;NVS;PTEN;STX;SF;XEL;ZIOP;VOLC;BXP;TEVA;RCL;MDLZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
June 25, 2015
08:04 EDTVOLCSecond Sight names Will McGuire as president and CEO, effective August 18
Subscribe for More Information
06:28 EDTBXPBoston Properties downgraded to Hold from Buy at Stifel
Subscribe for More Information
June 24, 2015
10:00 EDTRCLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:04 EDTTEVATeva launches PainMatters.com to support ‘responsible pain management’
Subscribe for More Information
07:30 EDTBXPUBS to hold a tour
Subscribe for More Information
June 23, 2015
18:44 EDTRCLRoyal Caribbean upgraded to Buy from Neutral at Goldman
Subscribe for More Information
14:16 EDTTEVABMO Capital sees strong fundamentals in Perrigo regardless of Mylan deal
Shares of Perrigo (PRGO) are trading higher intraday after BMO Capital Markets initiated coverage of the stock with an Outperform rating. The research firm is bullish on the shares regardless of whether Mylan's bid for the company succeeds, saying Perrigo is well-positioned to ride momentum in reduced-price healthcare. WHAT'S NEW: BMO Capital Markets' David Maris initiated coverage of Perrigo with an Outperform rating and a $246 price target. Maris cited the company's 70%-plus market share in store- and private-label brands, as well as its roughly $1B annual sales in the generics space. The analyst believes Perrigo will see continued benefit from larger trends driving consumer-centric healthcare and the curtailing of medical costs. WHAT'S NOTABLE: BMO Capital Markets noted that two upcoming Tysabri-related events are not accounted for by the Street, giving rise to a "significant" undervaluing of the shares. Mylan (MYL) has submitted multiple unsolicited offers for Perrigo, and while the likelihood of the deal seems low given Perrigo's numerous rejections and Teva's (TEVA) 4.61% blocking stake in Mylan. BMO Capital remarked that a failed deal should see "limited downside" for Perrigo. There could certainly be near-term volatility if a Mylan agreement doesn't materialize, but the analyst was confident in the well-positioned company's ability to deliver on both earnings per share and cash flow. PRICE ACTION: Shares of Perrigo are up nearly 2% in afternoon trading. The company saw a nearly 25% leap following Mylan's initial offer on April 8, though it has since dipped from that high.
12:54 EDTSTXPC concerns weighing on shares of Seagate, Western Digital
Subscribe for More Information
08:49 EDTTEVAMylan CFO to meet with Tel Aviv bourse head Wednesday, Reuters says
Subscribe for More Information
08:03 EDTMDLZMondelez renews global strategic partnership with Facebook
Subscribe for More Information
07:34 EDTPTENGlobal Hunter Securities to hold a conference
Subscribe for More Information
06:25 EDTSTXWestern Digital downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
06:25 EDTSFBarclays-Stifel deal marks end of Lehman legacy, Business Insider reports
Subscribe for More Information
June 22, 2015
19:56 EDTXELUtilities sector dips after EPA warns of 'significant risks' from climate change
Subscribe for More Information
10:00 EDTZIOPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:14 EDTZIOPOn The Fly: Pre-market Movers
Subscribe for More Information
08:02 EDTRCLRoyal Caribbean completes next phase of construction for Harmony of the Seas
Subscribe for More Information
07:59 EDTZIOPZiopharm downgraded on valuation, competition at BMO Capital
As noted earlier, BMO Capital downgraded Ziopharm Market Perform from Outperform. As reasons for the downgrade, the firm cited valuation, increased competition, and its belief that the company has fallen further behind its competitors. Target to $10 from $15.
06:29 EDTZIOPZiopharm downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
June 21, 2015
19:53 EDTTEVAMylan CEO says Teva's 4.61% stake may be 'illegal,' Bloomberg reports
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use